INM (InMed Pharmaceuticals Inc.) Business Value to Revenue

Public company logo of InMed Pharmaceuticals Inc. (INM)

InMed Pharmaceuticals minimizes clinical risks through the diversification of its development pipeline in ophthalmology and dermatology. The company's price-to-sales ratio clearly demonstrates the asset's valuation trend, where the 9048.78 level captures the current state. Revenues are based on the biosynthesis of rare cannabinoids, while a flawless scientific image ensures a high degree of trust for the brand within the medical community.

INM - InMed EV/Sales Multiple over the range 11/23/2025 - 11/09/2026

INM (InMed Pharma): analytical breakdowns and indicator data

- share price and consensus valuation forecast:
- business market valuation indicators:
Initial company analysis:InMed Pharmaceuticals
Mass-produced product of InMed Pharmaceuticals Inc

For InMed Pharmaceuticals (INM), which focuses on supplying rare cannabinoids to clinics, the key is to reconcile the enterprise value, accounting for net debt, with the volume of generated sales. By analyzing the EV/Sales multiple, an investor assesses the efficiency of revenue capitalization, where a sharp decline in values may indicate either undervalued assets or a systemic crisis in the company's profitability.